Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
Clin Infect Dis
; 39(7): 1038-46, 2004 Oct 01.
Article
in En
| MEDLINE
| ID: mdl-15472858
ABSTRACT
BACKGROUND:
Zidovudine, lamivudine, and efavirenz comprise a highly effective and well-tolerated triple regimen for antiretroviral-naive patients. Evaluating other unique nucleoside reverse-transcriptase inhibitor (NRTI) combinations for long-term viral suppression is desirable.METHODS:
This multicenter, randomized, double-blind noninferiority clinical trial compared the efficacy and safety of abacavir with that of zidovudine plus lamivudine and efavirenz in 649 antiretroviral-naive HIV-infected patients. The primary objective was a comparison of proportions of patients achieving plasma HIV-1 RNA levelsCONCLUSION:
Abacavir provided an effective and durable antiretroviral response that was noninferior to zidovudine, when combined with lamivudine and efavirenz.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Oxazines
/
Dideoxynucleosides
/
Zidovudine
/
HIV Infections
/
Lamivudine
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Clin Infect Dis
Journal subject:
DOENCAS TRANSMISSIVEIS
Year:
2004
Document type:
Article
Affiliation country:
United States